北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (4): 607-609. doi: 10.19723/j.issn.1671-167X.2020.04.001
• 专家笔谈 • 下一篇
雄激素剥夺治疗相关心血管疾病的机制与临床对策
徐涛1,△(
),韩敬丽1,姚伟娟2
- 1.北京大学人民医院泌尿外科,北京 100044
2.北京大学基础医学院生理学与病理生理学系,北京 100191
中图分类号:
- R697+.3
| [1] |
Gupta D, Lee Chuy K, Yang J C, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract, 2018,14(10):580-587.
pmid: 30312560 |
| [2] |
Farrell SO, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2015,33(11):1243-1251.
pmid: 25732167 |
| [3] |
Conteduca V, Lorenzo GD, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy[J]. Crit Rev Oncol Hematol, 2013,86(1):42-51.
doi: 10.1016/j.critrevonc.2012.09.008 pmid: 23092636 |
| [4] | Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer[J]. J Clin Oncol, 2006,24(27):4448-4456. |
| [5] |
Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction[J]. JAMA, 2009,302(8):866-873.
doi: 10.1001/jama.2009.1137 pmid: 19706860 |
| [6] |
Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer[J]. J Natl Cancer Inst, 2010,102(1):39-46.
pmid: 19996060 |
| [7] |
Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: A meta-analysis of population-based observational studies[J]. PLoS One, 2014,9(9):e107516.
doi: 10.1371/journal.pone.0107516 pmid: 25264674 |
| [8] | Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis[J]. Eur Urol, 2015,68(3):386-396. |
| [9] | Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review[J]. BMC Cancer, 2016,16(1):180. |
| [10] | Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health[J]. Mayo Clin Proc, 2018,93(1):83-100. |
| [11] |
Clinton TN, Woldu SL, Raj GV. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer[J]. Expert Opin Pharmacother, 2017,18(8):825-832.
doi: 10.1080/14656566.2017.1328056 pmid: 28480768 |
| [12] |
Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol, 2014,65(3):565-573.
pmid: 24210090 |
| [13] |
Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease[J]. J Urol, 2019,202(6):1199-1208.
pmid: 31188734 |
| [14] | A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease(PRONOUNCE)[Z/OL]. (2016-01-26)[2020-04-06]. https://clinicaltrials.gov/ct2/show/NCT02663908?term=NCT02663908&draw=2&rank=1. |
| [15] | Cone EB, Marchese M, Reese S, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists[J/OL]. BJU Int, 3(2020-03-30)[2020-04-10]. https://pubmed.ncbi.nlm.nih.gov/32232935/?from_single_result=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists&expanded_search_query=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists. |
| [16] | Bubley GJ. Is the flare phenomenon clinically significant?[J]. Urology, 2001,58(2):5-9. |
| [17] | Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice[J]. Sci Rep, 2016,6(1):26220. |
| [18] | Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis[J]. J Lipid Res, 2009,50(Suppl):352-357. |
| [19] |
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase Ⅲ study in patients with prostate cancer[J]. BJU Int, 2008,102(11):1531-1538.
pmid: 19035858 |
| [20] |
Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?[J]. Ther Adv Urol, 2016,8(2):118-129.
doi: 10.1177/1756287215617872 |
| [21] | Wang Q, Zhou J, Yao W, et al. Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation[J]. Eur Urol, 2019,18(Suppl 1):e72. |
| [22] |
Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer[J]. Circulation, 2016,133(5):537-541.
pmid: 26831435 |
| [1] | 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报（医学版）, 2021, 53(4): 686-691. |
| [2] | 郭子宁, 梁志生, 周仪, 张娜, 黄捷. 基于国际疾病分类的心血管疾病亚型的基因组学研究[J]. 北京大学学报（医学版）, 2021, 53(3): 453-459. |
| [3] | 刘秋萍,陈汐瑾,王佳敏,刘晓非,司亚琴,梁靖媛,沈鹏,林鸿波,唐迅,高培. 基于马尔可夫模型的社区人群心血管病筛查策略的效果评价[J]. 北京大学学报（医学版）, 2021, 53(3): 460-466. |
| [4] | 陈家丽,金月波,王一帆,张晓盈,李静,姚海红,何菁,李春. 老年发病类风湿关节炎的临床特征及其心血管疾病危险因素分析:一项大样本横断面临床研究[J]. 北京大学学报（医学版）, 2020, 52(6): 1040-1047. |
| [5] | 刘滕飞,林涛,任利辉,李广平,彭建军. CMTM5基因与冠状动脉粥样硬化性心脏病的关联研究及机制探讨[J]. 北京大学学报（医学版）, 2020, 52(6): 1082-1087. |
| [6] | 轩艳,蔡宇,王啸轩,石巧,邱立新,栾庆先. 牙龈卟啉单胞菌感染对载脂蛋白e基因敲除小鼠动脉粥样硬化的影响[J]. 北京大学学报（医学版）, 2020, 52(4): 743-749. |
| [7] | 刘欢,何映东,刘金波,黄薇,赵娜,赵红薇,周晓华,王宏宇. 血管健康指标对新发心脑血管事件的预测价值:北京血管健康分级标准的初步验证[J]. 北京大学学报（医学版）, 2020, 52(3): 514-520. |
| [8] | 李文卿,任思楣,龙星博,田雨青. 棕榈酰化蛋白质组学分析揭示前列腺癌细胞中雄激素促进代谢相关蛋白棕榈酰化修饰[J]. 北京大学学报（医学版）, 2020, 52(2): 227-233. |
| [9] | 孙奎霞,闫存玲,李志艳,刘平,张伟,何群. 前列腺特异性抗原同源异构体2及其衍生指标在预测前列腺癌病理分级中的价值[J]. 北京大学学报（医学版）, 2020, 52(2): 234-239. |
| [10] | 任川,吴晓月,赵威,陶立元,刘萍,高炜. 心肺适能对动脉粥样硬化性心血管疾病高危患者的保护作用[J]. 北京大学学报（医学版）, 2020, 52(1): 152-157. |
| [11] | 段丽萍,郑朝霞,张宇慧,董捷. 腹膜透析患者营养不良-炎症-心血管疾病与认知功能恶化的关系[J]. 北京大学学报（医学版）, 2019, 51(3): 510-518. |
| [12] | 张宽根,周雨禾,邵雅昆,梅放,由江峰,刘北英,裴斐. 肿瘤转移抑制基因LASS2/TMSG1 S248A突变体通过增加ATP6V0C表达促进前列腺癌的侵袭[J]. 北京大学学报（医学版）, 2019, 51(2): 210-220. |
| [13] | 张静,李素芳,陈红,宋俊贤. miR-106b-5p在调节内皮细胞基因表达谱中的作用[J]. 北京大学学报（医学版）, 2019, 51(2): 221-227. |
| [14] | 唐旭，赵卫红，宋琴琴，殷华奇，杜依青，盛正祚，王强，张晓威，李清，刘士军，徐涛. SOX10对前列腺癌细胞增殖及侵袭的影响[J]. 北京大学学报(医学版), 2018, 50(4): 602-606. |
| [15] | 司亚琴，唐迅，张杜丹，何柳，曹洋，王晋伟，李娜，刘建江，高培，胡永华. 北方农村人群心血管病一级预防筛查策略的评价[J]. 北京大学学报(医学版), 2018, 50(3): 443-449. |
|
